Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Adriamycin, Cytoxan, G-CSF, and Taxol in High-Risk Localized Breast Cancer
NCT00194753Phase 2Completed
- Sponsor
- University of Washington
- Start
- Dec 2001
- Primary completion
- Mar 2011
- Modality
- Targeted Liposomes, Cytokines & Interferons, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated liposomal doxorubicin, cyclophosphamide, Paclitaxel Micelles for Injection, filgrastim in breast cancer, sponsored by University of Washington. Started Dec 2001; status: completed.
02
Drugs
pegylated liposomal doxorubicincyclophosphamidePaclitaxel Micelles for Injectionfilgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00194753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00194753.